IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 63.62

Change

-1.40 (-2.15)%

Market Cap

N/A

Volume

0.14M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-13 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-4.09 (-3.01%)

USD 35.08B
FHLC Fidelity® MSCI Health Care In..

-1.78 (-2.77%)

USD 2.50B
FXH First Trust Health Care AlphaD..

-1.10 (-1.07%)

USD 0.89B
XHE SPDR® S&P Health Care Equipme..

-0.74 (-0.89%)

USD 0.16B
IDNA iShares Genomics Immunology an..

-0.44 (-2.23%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

-0.84 (-0.85%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

-0.70 (-2.48%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.05 (-0.19%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

-1.44 (-2.59%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.32 (-1.78%)

USD 0.01B

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.20% 76% C+ 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.20% 76% C+ 32% F
Trailing 12 Months  
Capital Gain -3.20% 76% C+ 33% F
Dividend Return 0.99% 88% B+ 21% F
Total Return -2.20% 76% C+ 28% F
Trailing 5 Years  
Capital Gain 24.89% 62% D 42% F
Dividend Return 8.91% 95% A 19% F
Total Return 33.80% 71% C- 36% F
Average Annual (5 Year Horizon)  
Capital Gain 2.81% 67% D+ 48% F
Dividend Return 4.19% 67% D+ 44% F
Total Return 1.38% 100% F 33% F
Risk Return Profile  
Volatility (Standard Deviation) 14.27% 62% D 67% D+
Risk Adjusted Return 29.36% 67% D+ 47% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike